Sign in to view Stephanie’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Tulsa, Oklahoma, United States
Contact Info
Sign in to view Stephanie’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
9K followers
500+ connections
Sign in to view Stephanie’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Stephanie
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Stephanie
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Stephanie’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Licenses & Certifications
-
Certified in Sign Language
-
-
HIPAA Compliance Certificate
-
Languages
-
Sign Languages
-
-
French
-
-
French
Limited working proficiency
-
Spanish
Limited working proficiency
-
English
Native or bilingual proficiency
-
Thai
Elementary proficiency
View Stephanie’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Anna Schwabe, PhD
Forked River, NJConnect -
Daniel Fowler, PhD
Cannabis Science and Genetics 🧬 Co-Founder and CSO, S3 🧬 Gene Editing 🧬 BetterCannabisThroughScience Consulting 🧬 Molecular Biologist 🧬 Outdoors Enthusiast
Denver Metropolitan AreaConnect -
Jeff Rawson
President, Institute of Cannabis Science, cannsci.org
Cambridge, MAConnect -
Gaurav Sehgal
BangkokConnect -
Sakesan Akaros
Founder at Zomia Collective
BangkokConnect -
Paul Crosio
Partner @ Silk Legal | Notary Public and Practising Lawyer- Former Investment Banker and Economist
BangkokConnect -
Brian Jester
Atlanta Metropolitan AreaConnect -
Colin Clark
Fort Collins, COConnect -
Dustin Hoxworth
Atlanta, GAConnect -
Nutthachai Na Sua
Bangkok City, ThailandConnect -
Truong M Nguyen
PhitsanulokConnect -
Dwight Diotte
CanadaConnect -
Monica Garcia
BangkokConnect -
Nick Pargaz
Las Vegas, NVConnect -
Alan Sutton
ElyConnect -
Willie McKenzie
Manistee, MIConnect -
Jill Carreiro
Greater BostonConnect -
Paul Sidhu (Security Cleared)
Toronto, ONConnect -
John Nathan
Plymouth, MAConnect -
Pornchai Padmindra
BangkokConnect
Explore more posts
-
Melody Woolf
Kratom deaths? Kratom the only thing in their system? Its hard to tell COD because of synthetic cannabiboids. They don’t show up in drug tests. And look at effects CDC “Synthetic cannabinoids are not detectable on most standard in-house hospital drug screens, including assays for tetrahydrocannabinol (THC).” https://lnkd.in/gbhj6SZT Kratom deaths? Maybe or maybe not. Regarding substances how accurate are coroner reports of COD? There are several reasons they might not be too accurate. ““should be aware that immunoassay screening will not detect most novel hallucinogens.” https://lnkd.in/gHrf8Zss
6
-
Kyla Norton
Cyclic Vomiting Syndrome and Cannabinoid Hyperemesis are as real as cannabis testing fraud. How do they impact each other? . . . There are extensive examples of cannabinoid hyperemesis from consumers that grew their own and still got sick. CHS exists outside of pesticide poisoning. The conditions are NOT the same. However, what if a patient has BOTH? The most severe cases, where multi system organ failure and deaths occcur, need toxicology for commercial growing agents. What tools do clinicians have for differential diagnosis? Emetic disorders and/ or pesticide poisoning? [If your hospital system has lab panels for cannabis pesticides send me a message please!] What is the severity of disease with isolated CVS or CHS in a patient that ALSO has toxicity from commercial pesticides? It’s very common for CVS patients to consume cannabis to treat CVS. Amongst this sub population, are medical cannabis consumers that are limited in product choices. With specific brands of cannabis increasing symptoms, and others providing relief… I have to question the growing agents used commercially. This post is NOT to entertain the theory that CHS = pesticide poisoning. This is about how pesticide toxicity could further impact a CHS and CVS patients journey. And the lack of tools clinicians have to navigate such complex cases. With such limitations of the testing industry…It is not sufficient to pull the COAs from products consumed to evaluate if there has been exposure. Actual labs need to be drawn from the patient. [Are you developing this/ would your lab be down? Would love to hear from you!!!] Ultimately, I am curious if toxicology panels for commercial growing agents are created… will we catch testing fraud when patients come into hospital sick as can be with positive labs? 🤔 Thank you to the patients for sharing and educating the public so far! As well as the academics and professionals that respectfully engage in this topic.
13
11 Comments -
Rebecca Michelle Norris
Advocating for Accountability: Strengthening Louisiana’s Pet Industry Louisiana's ranking near the bottom of various lists is a well-known reality, but have we truly examined the impact on specific sectors such as the pet industry? The lack of a regulatory entity coupled with nonexistent legislation poses significant challenges, allowing unscrupulous individuals to exploit the industry for financial gain while jeopardizing animal welfare. It's time to address these issues head-on and advocate for much-needed reforms to protect our furry companions and uphold industry standards. The absence of a regulatory body in Louisiana's pet industry leaves business owners unchecked, fostering an environment ripe for exploitation. Without oversight, undertrained and underqualified individuals may operate unethical businesses, putting the well-being of pets at risk. Mobile units, doggy daycares, grooming facilities, and boarding establishments should all be subject to state inspections to ensure cleanliness, ethical practices, and appropriate training and certification of staff. The lack of comprehensive laws exacerbates the challenges facing Louisiana's pet industry. Unlike other states where incidents such as pet deaths or injuries must be reported, Louisiana lacks legal mandates for such disclosures. This loophole not only compromises transparency but also denies pet owners critical information about the safety and reliability of pet-related businesses. It's imperative that legislation be enacted to require reporting of incidents and to establish industry standards for training, certification, and ethical conduct. As pet professionals and advocates, we have a moral obligation to speak up for those who cannot speak for themselves. The safety and well-being of pets should be our top priority, and advocating for regulatory reforms is a crucial step in fulfilling that responsibility. By pushing for accountability measures, we can protect pets from harm and ensure that pet-related businesses operate ethically and responsibly. Effecting meaningful change in Louisiana's pet industry requires collaborative efforts from all stakeholders involved. Pet owners, industry professionals, lawmakers, and advocacy groups must come together to champion regulatory reforms and uphold standards of excellence. By working collectively, we can create a safer and more transparent environment for pets and pet lovers across the state. Louisiana's pet industry is in dire need of accountability and regulation. By addressing the regulatory void and advocating for comprehensive legislation, we can protect pets from exploitation and ensure the integrity of pet-related businesses. Let us be the voices for those who cannot speak and the guardians of their safety and well-being. Together, let's push for the changes needed to strengthen Louisiana's pet industry and uphold our commitment to animal welfare.
-
Juan Alicea
NORML The US Drug Enforcement Administration is now accepting comments from the public until July 22, 2024 on whether to reclassify cannabis. NORML's step-by-step submission guide and talking points will assist you in taking part in this once in a lifetime opportunity to help shape federal cannabis policy. Take Action This is a unique opportunity for patients, physicians, state-licensed business owners, and others to provide first-hand insight to administrators affirming the safety and efficacy of cannabis, as well as the economic opportunities afforded by legal cannabis markets. The US Department of Health and Services based its recommendation largely upon real-world clinical evidence gathered from legal states. Your submission will help to reaffirm their conclusions that cannabis “has a currently accepted medical use” and that its abuse potential does not warrant its placement as either a Schedule I or Schedule II controlled substance. SUBMIT YOUR COMMENTS We have provided comments for you that affirm and further substantiate HHS’ historic recommendations. But in order to maximize the influence of these submissions, we are asking you to personalize them so that they reflect your unique story. For example, if you are a patient who has been able to reduce your use of opioids with medical cannabis, please share your experience. If you reside in a state where medical cannabis is legal and you have witnessed the positive health and economic impacts of this policy change, please elaborate. If you are a physician and you have seen your patients respond favorably to cannabis therapy, now is the time to share your expert opinion. If you operate a state-licensed cannabis business and you have been struggling to make ends meet because of 280E requirements, explain how this federal policy change will benefit you economically. Your stories hold power. But they won’t be the only stories regulators hear. Our political opponents are encouraging their members to weigh in with negative comments urging administrators to keep cannabis in Schedule I. We must push back against their scare tactics and sensational claims. We must do so with one voice and by providing a clear and concise message: That cannabis has legitimate medical utility and that it doesn’t possess the same potential for abuse as substances in either Schedule I or Schedule II. While NORML strongly believes that cannabis should be removed from the CSA altogether – thereby harmonizing federal cannabis policy with those of most US states – we nonetheless do not oppose the factual basis underlying HHS’ recommendation to move botanical cannabis to Schedule III or lower. That is why we have been coordinating with other reform groups in recent weeks so that we, as a movement, can deliver a consistent persuasive message. This is your opportunity to influence the most significant change in federal marijuana law in over five decades. Please send your public comment
-
Jacob Sager
Can we talk about Gas Station weed? The convenience store near me Is selling up to an extra thousand dollars a day Of Cannabis beverages and smokes. I live in Texas, it’s all farm bill compliant Hemp derived cannabinoids. Some products are shelved by distributors who have a direct relationship with the store, other SKUs the get wholesale At the same place they get candy bars and travel size Advil. This is the “fancy” convenience store across from the neighborhood elementary school. This retail selling of farm bill hemp Like they sell alcohol and tobacco Seems to be working? I have not read on any major health crisis nor of further corruption of the youth. So while it’s not Colorado dispensary weed, the farm bill compliant delta 9 and thca products aren’t too far off… Which begs the question: Are dispensaries really necessary For public health and safety For public sale of recreational cannabis? I, for one, think no. What do you think?
-
Jaron Gladstone
Incredibly sad that we have proven safety associated to naturally present cannabinoids in cannabis such as cbd, cbg, and cbc as depicted in this 12 week trial. https://lnkd.in/dd5qrTxy? and yet we have bills like the Miller bill and others that not only lack industry knowledge but also education or lived experience. It Is easy to make decisions on behalf of special interest groups when you are not personally impacted. Levering outside forces such as faulty marketing practices (claiming marketing to children), the use of unestablished alternatives such as HHC has led to the legislative perspective we need to “save” the kids, and regulate this harder. My belief in reality, while likely not a popular one, all distillate included thc, cbd, and other major cannabinoid should be produced and derived from low potency cannabis otherwise know as hemp, why? Well the scalability, cost and turn over makes business sense and is practical to meet the scale needed for consumers. Traditional cannabis will become more based on qualitative metrics rather then only quantitive. We will see a model that reflects the wine experience, frankly total thc will become less relevant once consumers and brand actually market and depict all the relevant info associated to the goods such as total VOCs including terpene, Flavinoids, esters (flavor compounds) and other actives. People will shop for experience not numbers. Concentrates will have their place to as a true experience of what that plant has to offer in a compact form without the need for combustion. Just like other personalization experiences cannabis will too become that if not sucked into a pharma only paradigm. It’s a shame many of the players doing right by their end users are getting the short hand of the stick due to the discrepancy of perception versus reality. There is proven efficacy for those who has taken an alternative approach to their health I don’t think this interference is warranted.
1
-
Benjamin Caplan, MD
Here, sharing an article I contributed to: "Rescheduling of Cannabis: What the Experts Think" on CBD Oracle. 🚀 This compilation joins thoughts from a dozen industry experts, around what moving cannabis from Schedule I to Schedule III could mean for everyone involved – from users and researchers to businesses and policymakers. I had the chance to share my thoughts alongside a strong group of other experts in the field. We covered a lot of ground, from legal implications to scientific research and economic impacts. It’s a comprehensive look at a topic that’s more relevant than ever. Check it out the summary here: https://lnkd.in/es5E745R Or the full interviews here: https://lnkd.in/euGCHbiQ This discussion isn't going anywhere... no matter who gets elected, cannabis will be front and center of human culture from now on... Certainly so, if there's anything I have to say about it! 😉 Let’s keep the conversation going! 🌿💬
13
5 Comments -
Brendon Roberts
Cannabis is well-known for its diverse range of beneficial compounds, and one of the standout components is β-caryophyllene. This terpene, also found in guava & cannabis, has garnered attention for its significant positive effects on skin health. β-Caryophyllene exhibits strong antioxidant and antibacterial activities, making it a powerful ally in the fight against skin aging and infections. By neutralizing free radicals, it helps to prevent oxidative stress, a major contributor to skin damage and premature aging. Its antibacterial properties further protect the skin from harmful bacteria, promoting a clearer, healthier complexion. One of the remarkable benefits of β-caryophyllene is its ability to inhibit tyrosinase and collagenase enzymes. Tyrosinase plays a crucial role in melanin production, and its inhibition can lead to a significant whitening effect, with studies showing up to a 99% improvement. Collagenase breaks down collagen, and by inhibiting this enzyme, β-caryophyllene helps maintain skin structure and reduce wrinkles, showing a 97% improvement in wrinkle appearance. Another notable benefit of β-caryophyllene is its ability to remove trans-2-nonenal, a compound associated with aging-related body odor. This results in a 54% reduction in odor, contributing to a fresher and more pleasant skin scent. Given its impressive range of benefits, β-caryophyllene holds great potential as a functional ingredient in both cosmetics and health foods. Its natural properties offer a holistic approach to enhancing skin health and appearance. Beyond cosmetic benefits, β-caryophyllene also plays a significant role in skin health through its antioxidant and anti-inflammatory effects. It aids in the wound-healing process by supporting the overlapping and interdependent phases of healing. This can lead to reduced physical and psychological deficiencies associated with unhealed wounds, promoting overall skin wellness. β-Caryophyllene is a powerful agent for skin enhancement and health. From antioxidant and antibacterial actions to enzyme inhibition and wound healing, its diverse benefits make it a promising ingredient for future skincare and health food products. Let's embrace the potential of β-caryophyllene for healthier, more radiant skin. High β-Caryophyllene flower illustration attached 👇🏾 #cannabis #cannabisindustry #cannabiscommunity
188
56 Comments -
Adendox
🌿 Texas Senate Considers Delta-8 THC Ban 🌿 On May 29, 2024, the Texas Senate Committee on State Affairs held hearings on a proposed Delta-8 THC ban. Key points for lawmakers: ➡️ Need for Quality Control: Laws should ensure quality standards for all cannabinoid products. ➡️ Regulatory Models: Cannabis regulatory framework should align with national and global trends. Balanced regulation is essential for safety and market stability. Stay informed, full article here: https://lnkd.in/gmwRvePT #CannabisRegulation #MedicalCannabis #Delta8THC #TexasCannabis #TCUP #Safety #CannabisEducation #BluebonnetWellness
2
-
Yasmine Jeannette Egozi
Legally, I can't recommend this, but it's worth noting that cannabinoids are naturally present in breast milk. This raises an important question: if our bodies naturally produce cannabinoids, can they really be harmful? Many of my pregnant clients have faced challenges, especially during the first trimester, with the urge to continue to consume THC. Those who have transitioned to CBD flower have found success and provided them relief without any issues. Ultimately, the decision is personal. Empower yourself with knowledge and choose what feels right for you. #CBD #Pregnancy #Wellness #NaturalHealing
969
44 Comments -
Cameron Bell
Just pressed a few rosins with Nicholas Dell the other night. We pressed about 35 grams & based primarily on the profiles + quality of the press alone - I’m expecting some heat when the curing process is done. ✅🥵 In flower, they tested as follows: Animal Face 35% THC, 3.1% terps (dominant in B-Caryophyllene, Myrcene is secondary, with Limonene, Linalool & Humulene competing for third - near equal amount of bisabolol too) Hazel Eclipse 28% THC, 3.5% terps, 1.5% CBG (dominant in Terpinolene, then myrcene, a few sativa-esque terps fight for third) Black Afghan 26% THC, 3.5% terps, hint of CBG (very dominant in Myrcene, Ocimene & A-Pinene tie for second, B-Caryophyllene at 3rd) Cobalt Cream 30% THC, 3% terps, 2.8% CBG (B-Caryophyllene & Limonene tie for first, Myrcene is second, Humulene at third) Lemon Wafer 27% THC, 2.8% terps, hint of CBG (dominant in A-Pinene, Myrcene, B-Pinene, hint of nerolidol) I selected very carefully & will keep you guys updated with posts throughout the week! 🫡
11
-
Brian Dombrowski
If you don’t know who AJ Velador is, now you know. Thank you brother. "Good Evening Hemp Friends, AJ here, I’m pretty sure yall know me by now and the ones who don’t please ask around because I’ve been in trenches with all of you during the inception of Hemp in Texas and the U.S. I have retail shop, wholesale operations and farms. My partners and myself are prepared to donate $250,000 in an effort to lobby a bill that will regulate our industry in an effort to save it for all of us. Our days are numbered and we have 1 year or less before a ban on Delta 8/ THCA is coming. We are NOT asking for donations but rather your support in the the months to come. We will be forming a committee of entrepreneurs and activists whom want to participate in our endeavor to keep legal Hemp THC approved in Texas. Again, we are Not requiring any financial obligations other than your time and support. “ Help us to Help you!” My partners and myslef will cover the cost of our lobbying efforts and have already recruited Top Cannabis Attorneys to draft our bill. Once we form a committee of industry leaders throughout Texas we will most likely host 3 committee meetings in the following cities; Houston, Dallas, & Austin. The purpose of our committee and its members will be to delegate responsibility to achieve our independent goals that the committee will adopt and have to execute. We will have a 3 part plan that we need help on all sides to accomplish the different segments that will encompass; Drafting regulations for Bill, media/Community Service agendas, petitions of registered voters and call to action of 100k voters outside Court house that we plan to make headline global news. More to follow on this."
96
36 Comments -
Elwan Dwi Nugroho
Recommended Initial Kratom Dosage For those new to Kratom, starting with a low dosage is paramount to ensure a safe and positive experience. A general recommendation is to begin with a dose of 1 to 2 grams. Pay attention to your body’s response over the next 30 to 45 minutes. If the effects are not felt after this period, you might consider a small additional dose of 0.5 to 1 gram. It’s crucial to start low and go slow, as the compound’s effects can vary widely among individuals due to factors such as body weight, metabolic rate, and overall tolerance to opioid-like substances. #nature #europe #czech #praha #kroměříž #olomouc #ČeskýKrumlov #KutnáHora #unitedstates #Burgenland #Niederösterreich
1
-
Robb Harmon
Lesser-Known Marijuana Components Can Be ‘Promising Anticancer Agents,’ Study On Multiple Myeloma Finds A new study on the possible therapeutic value of lesser-known compounds in cannabis says that a number of minor cannabinoids may have anticancer effects on blood cancer that warrant further study. The research, published in the journal BioFactors, looked at minor cannabinoids and multiple myeloma (MM), testing responses in cell models to the cannabinoids CBG, CBC, CBN and CBDV as well as studying CBN in a mouse model. “Together, our results suggest that CBG, CBC, CBN, and CBDV can be promising anticancer agents for MM,” authors wrote, “due to their cytotoxic effect on MM cell lines and, for CBN, in in vivo xenograft mouse model of MM.” https://lnkd.in/e_wgi23f?
-
Jonathan Simcic
The Drug Enforcement Administration (DEA) has made an extraordinary decision, aligning with the top federal health agency to shift marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This momentous step comes after more than fifty years since cannabis was initially listed as a strictly prohibited substance, equated with heroin, devoid of any recognized medical benefits, and carrying a significant potential for abuse. The reclassification of marijuana to Schedule III, as advised by the U.S. Department of Health and Human Services (HHS), carries immense implications for state-legal cannabis businesses. Upon implementation, this move will enable cannabis companies access to federal tax deductions that were previously off-limits to them under the IRS code, section 280E. #reschedule #cannabisindustry #280e #bloommedicinals #wondergrovecannabis #msos #medicalcannabis
22
4 Comments -
Daniel Fowler, PhD
Two things I wanted to address on this because it absolutely exploded in my network. Disclaimer: I've got no skin in this game. These are observations based on all the shitposting I saw yesterday. The rundown is that Mass gave a cease and desist to Bay State Extracts for THCV. That's it. That's all we know. 1) The conspiracy theories came out hard as they tend to do with cannabis people. One was that Pharma was behind this because THCV is going to cut into sales of GLP1 drugs like Ozempic. Another was something something GW pharma because Schedule 3. (BTW SIII hasn't happened yet). There were plenty of others. I for one am getting tired of this crap. Please pump the breaks (you know who you are) unless you've got some evidence to share, or at the least can explain how any of these theories would work. For example, how would a patent on Ozempic (a GLP1R agonist) cause a state regulatory body to pursue legal action for a cannabinoid? Let's apply Occam's razor here please: what is more likely? - that a state is regulating hemp derivatives or that there is a massive Pharma conspiracy at play? 2) This highlights natural cannabinoids are at risk due to hemp synthetic derivatives. THCV is actually a natural cannabinoid (unlike d8 or HHC). It has been bred to dominance and is available via flower or THCV rich extracts. THCV is also made via semi-synthesis and even biosynthesis through engineered fermentation systems. These all have pros and cons, and I'm not here to figure out what Bay State was using. My point is that some regulators and politicians don't understand the difference, and while regulating the non-natural derivatives, that natural sources could be axed as well. This puts all the natural noids at risk. Varins, CBG, CBC, CBN - even CBD and THC. Be smart. Be safe. Be kind ✌️ https://lnkd.in/gxVFa5GV
52
24 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More